A phase I clinical study investigating the safety of subcutaneous Elafin, an elastase inhibitor that inhibits neutrophil elastase, as a treatment for severe PAH has been completed (ClinicalTrials.gov:NCT03522935), highlighting the translational potential for targeting elastase and cathepsin pathways in PAH33,34. The gene discussed is ELANE; the disease is pulmonary arterial hypertension.